Daiichi Sankyo and MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) have expanded their existing global co-development and co-commercialization agreement for three investigational DXd antibody-drug conjugates to include MSD’s MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager. The companies will jointly develop and commercialize MK-6070 worldwide, except in Japan where MSD will maintain exclusive rights. MSD will be solely responsible for manufacturing and supply for MK-6070. Read more.
